secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0000950170-24-070584
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology stockholders approve 5.5M share increase to equity plan at June 5 annual meeting
--------------------------------------------------------------------------------

- Stockholders approved Amended 2014 Plan, increasing authorized shares by 5.5M to total 29,827,686 shares.
- Troy E. Wilson and Faheem Hasnain elected as Class I directors until 2027 annual meeting.
- Ratification of Ernst & Young as auditor for FY2024 approved (69.6M for, 56.7K against).
- Advisory vote on executive compensation approved with 61.5M for, 5.4M against.
- About 69.8M of 76.2M outstanding shares were represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017024070584/0000950170-24-070584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017024070584/kura-20240605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-070584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer